Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Noscira SA

Division of PharmaMar SA/Zeltia SA

Latest From Noscira SA

Noscira's novel Alzheimer's drug shows promise in Phase II

Noscira's novel Alzheimer's disease-modifying oral drug candidate Nypta (tideglusib; NP-12) has achieved positive results in a Phase IIa study presented at the recent International Conference on Alzheimer's disease (ICAD) in Hawaii.

Neurology Clinical Trials

Yondelis drives Zeltia Group's biopharmaceutical business

Yondelis (trabectedin) again drove the Spanish biotech group Zeltia's first-quarter business and helped the group's EBITDA break even.

Cancer Neurology

Recent Financings of Private Companies (02/2007)

Each month, Start-Up presents a comprehensive review of young, private life science companies that have recieved venture funding during the month, including companies in the pharmaceutical, medical device, diagnostic and research instrumentation & reagent sectors.
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Neurology, Nervous System
  • Alias(es)
  • Neuropharma SA
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • Spain
  • Parent & Subsidiaries
  • PharmaMar SA
  • Senior Management
  • Contact Info
  • Noscira SA
    Phone: (34) 91 806 11 30
    Avda. de la Industria 52
    Madrid, 28760